1. Home
  2. CYCU vs CLGN Comparison

CYCU vs CLGN Comparison

Compare CYCU & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cycurion Inc.

CYCU

Cycurion Inc.

N/A

Current Price

$1.60

Market Cap

7.8M

Sector

N/A

ML Signal

N/A

Logo CollPlant Biotechnologies Ltd

CLGN

CollPlant Biotechnologies Ltd

N/A

Current Price

$0.62

Market Cap

18.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CYCU
CLGN
Founded
2017
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8M
18.4M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
CYCU
CLGN
Price
$1.60
$0.62
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$7.00
$11.00
AVG Volume (30 Days)
79.3K
84.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1,596.12
Revenue Next Year
$5.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.50
52 Week High
$7.13
$4.98

Technical Indicators

Market Signals
Indicator
CYCU
CLGN
Relative Strength Index (RSI) 37.46 33.59
Support Level $1.62 $0.50
Resistance Level $2.91 $1.60
Average True Range (ATR) 0.14 0.07
MACD 0.03 0.04
Stochastic Oscillator 31.55 53.19

Price Performance

Historical Comparison
CYCU
CLGN

About CYCU Cycurion Inc.

Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).

About CLGN CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.

Share on Social Networks: